New meningitis vaccine trial aims to protect babies

NCT ID NCT07505823

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Sinovac Biotech Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This Phase 3 trial tests a new vaccine against four types of meningococcal bacteria (A, C, Y, W135) that cause meningitis. About 1,040 healthy infants aged 6 to 11 months will receive either the experimental vaccine or a licensed comparator. Researchers will measure immune responses and track side effects to see if the new vaccine is as safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Group ACYW135 Meningococcal Conjugate Vaccine
What this could lead to: If successful, this could provide a safe and effective vaccine to protect infants against four types of meningococcal bacteria that cause meningitis.
What could go wrong: This is an early-stage Phase 3 trial, and the vaccine may not prove as effective or safe as the existing licensed vaccine. Results are based on immune markers, not actual disease prevention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPIDEMIC MENINGITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

meningitis meningococcal meningitis meningococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPIDEMIC MENINGITIS MENINGOCOCCAL VACCINES

Contacts and locations

Locations

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention
RECRUITING

Nanning, Guangxi, 530028, China
Shanxi Provincial Center for Disease Control and Prevention
RECRUITING

Taiyuan, Shanxi, 030032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.